This is a preview of subscription content, log in via an institution to check access.
Reference
Rodwin MA, et al. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017. European Journal of Cancer 145: 11-18, 4 Jan 2021. Available from: URL: http://doi.org/10.1016/j.ejca.2020.11.031
Rights and permissions
About this article
Cite this article
Prices of cancer drugs increase in France despite little added benefit. PharmacoEcon Outcomes News 870, 22 (2021). https://doi.org/10.1007/s40274-021-7425-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7425-5